Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™
Launched by 4TECH CARDIO LTD. · Mar 25, 2014
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
Implantation Procedure: Unlike the standard open chest, arrested heart approach, the 4TECH TriCinch System™ provides a percutaneous solution for tricuspid valve regurgitation treatment: this procedure is performed through deep sedation, while the heart is beating, without the need for respiratory assistance.
The TriCinch System™ consists of a Delivery System that enables transcatheter placement of an implant that can be adjusted to correct Tricuspid valve regurgitation. The TriCinch Delivery System is inserted from the femoral vein to access the right atrium of the heart. At the end of the...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Functional symptomatic tricuspid regurgitation (TR) 2+ to 4+ on a scale of 4+ (moderate to severe), with annular dilatation greater than 40mm.
- • Signed informed consent form prior to any study-related procedure.
- • Available and able to return to the study site for post-procedural follow-up examination
- • Eighteen (18) years of age or older.
- Exclusion Criteria:
- • Requirement for concomitant cardiac procedure (other than atrial fibrillation correction surgery, closure of PFO (Patent Foramen Ovale) or ASD (Atrial Septal Defect), or PTCA (percutaneous treatment of coronary artery) or CAD (coronary artery bypass surgery) from 1 to 3 months after or before other procedure.
- • Presence of any known life threatening (non-cardiac major or progressive disease), non-cardiac disease that will limit the subject's life expectancy to less than one year.
- • Cerebro-vascular event within the past 6 months.
- • History of mitral/tricuspid endocarditis within the last 12 months.
- • Organic tricuspid disease.
- • Contraindication or known allergy to device's components, aspirin, anti-coagulation therapy or contrast media that cannot be adequately premeditated.
- • Severe hypertension (SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg, measurement done by sphygmomanometer with stethoscope, allow the patient to sit for at least 5 minutes before beginning BP measurements).
- • Female patient is pregnant (urine HCG test result positive) or lactating.
- • Known alcohol or drug abuser.
- • Currently participating in the study of an investigational drug or device.
- • At heart team's judgement, patient IVC dimension is not adequate for device implantation.
About 4tech Cardio Ltd.
4tech Cardio Ltd. is a pioneering medical device company dedicated to advancing cardiovascular health through innovative technologies. Specializing in the development of minimally invasive solutions, the company focuses on enhancing patient outcomes by addressing unmet clinical needs in the treatment of cardiovascular diseases. With a commitment to rigorous research and clinical trials, 4tech Cardio Ltd. aims to deliver safe and effective products that improve the quality of life for patients worldwide. Through collaboration with healthcare professionals and regulatory bodies, the company strives to maintain the highest standards of safety and efficacy in its offerings.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Padova, , Italy
Toulouse, , France
Lyon, , France
Paris, , France
Paris, , France
Bonn, , Germany
Frankfurt Am Main, , Germany
Hamburg, , Germany
Milan, Lombardy, Italy
Pisa, Tuscany, Italy
Catania, , Italy
Massa, , Italy
Milano, , Italy
Roma, , Italy
Nieuwegein, , Netherlands
Patients applied
Trial Officials
Antonio Colombo, MD
Principal Investigator
San Raffaele Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials